Laplace Interventional Secures $22M Series C Financing to Advance Laplace TTVR System for Tricuspid Regurgitation

Mar 20, 2025 17:29 CST Updated 17:29

Laplace Interventional

Transcatheter Tricuspid Valve Technology Developer

Call for Partners: 2025 Global Surgical Robotics Conference

Registration: First Global Ophthalmology Conference | Tentative Agenda

Registration: First Global Cardiovascular Conference | Award Registration

Registration: The First Global Orthopedics Conference | Award Registration

Heart Future

Recently,Laplace Interventional Announcement Completed$22 million(approximatelyRMB 160 million) ofSeries CFinancing, to supportLaplace TTVR SystemDevelopment.

This round of financing was led by an undisclosed global strategic investor, with new investors Aphelion Cardeation and Unorthodox Ventures participating. Existing investors Engage Venture Partners, JWC Venture, and Features Capital also joined this round. The funds will be used to complete the Early Feasibility Study (EFS) and advance the approval of pivotal trials.

The Laplace TTVR System, developed by Laplace Interventional, is aTranscatheter Tricuspid Valve Replacement System, aiming to replace the tricuspid valve through minimally invasive surgery, providing treatment for patients with tricuspid regurgitation (TR), avoiding open-heart surgery, thereby reducing complications and improving the quality of life for patients.

Currently, the tricuspid regurgitation treatment market is mainly dominated by Edwards Lifesciences.Evoque Tricuspid valve involvement, this product was the first trans-catheter therapy approved last year for the treatment of TR. Abbott'sTriClipDevices are also competing in this field, in addition, CroíValve's DuoThe tricuspid valve docking system may also become a strong competitor.

# Executive Evaluation

Founder and CEO of Laplace InterventionalRamji Iyer "This round of financing is an important milestone for the company, further validating the progress we have made in the past few years. We are grateful for the continued support from patients, doctors, and both new and existing investors, and we look forward to launching the pivotal trial soon."

"Aphelion Cardeation, a venture fund that aims to invest in innovative healthcare products, services, and technologies aligned with the mission of the American Heart Association, is proud to participate in this round of financing. The Laplace TTVR system and its potential to transform care for millions of patients worldwide are truly inspiring," said Ned Scheetz of Aphelion Capital.

# About Laplace TTVR System

Laplace TTVR System is a treatment used forSevere or Symptomatic Tricuspid RegurgitationA New Type of Minimally Invasive Surgical Technique.

The system is inserted through subcutaneous blood vessels, avoiding traditional open-chest surgery, thereby reducing surgical risks and complications. The system allows for repositioning or retrieval of the valve during the procedure to ensure optimal placement and function. Additionally, its design can accommodate different anatomical structures, such as large annuli, ventricular structures, and native leaflet abnormalities.

The procedure for implanting the Laplace TTVR system includes several key steps:

1. Patients need a comprehensive evaluation, including multi-modal imaging to assess tricuspid valve anatomy and function.

2. The patient receives local anesthesia, and the doctor inserts a catheter through the vein to guide the valve to the tricuspid valve position.

3. Guided by imaging technology, ensure the correct position and deployment of the valve.

4. Patients are closely monitored postoperatively to ensure proper valve function and to observe for any complications.

▲Laplace TTVR Implantation Process

# Relevant Clinical Trials

In February 2024, Laplace Interventional announced the completion of the first-in-human surgery using its transcatheter tricuspid valve replacement system.The surgery was performed at the Heart and Vascular Institute of the Tucson Medical Center in the United States and under an FDA-approved early feasibility study clinical protocol to evaluate the system's feasibility and safety. The device is still under development and has not yet received approval from U.S. or other regulatory authorities.

As of March 2025, Laplace has been in the United States for22 namesThe patient underwent an early feasibility study (globally25NameThe patient), demonstrating excellent performance. Dr. Brandon Jones, an interventional cardiologist and director of the Center for Structural Heart Disease at Providence St. Vincent Medical Center in Portland, Oregon, stated,The Laplace TTVR system is intuitive to operate, has low imaging requirements, and is very convenient to use in various complex anatomical structures.

# Market Prospects and Challenges

The Market Potential for Transcatheter Tricuspid Valve Replacement is Enormous

Tricuspid RegurgitationIt is a common type of heart valve disease, accounting for approximately 60% of all types of tricuspid valve diseases. Its prevalence is age-related, and with the accelerating process of aging, the incidence rate is increasing.

According to relevant research data,In people aged 65 and above, the incidence rate of tricuspid regurgitation is as high as over 20%. This means that among every five elderly individuals, one may potentially suffer from tricuspid regurgitation.

Patients with tricuspid regurgitation generally have a low quality of life and high mortality rate.Approximately 36% of patients with severe tricuspid regurgitation die within one year of diagnosis, and about 47.8% die within five years of diagnosis. Among patients with mild or trivial regurgitation, 19% progress to moderate or severe regurgitation within three years.

However, the long-term efficacy of drug treatment for reflux is poor, and the mortality rate of surgical tricuspid valve surgery is high, hence there is a strong demand for interventional treatment.

From the perspective of market demand, transcatheter tricuspid valve technology offers advantages that traditional treatment methods cannot match, as it meets patients' needs for minimally invasive surgery.Reduce surgical trauma and recovery time, improve quality of life 。

Therefore, whether considering the current number of patients or the technical advantages, the market prospect of transcatheter tricuspid valve technology is very broad and is expected to become a new hotspot in the medical market.

Challenges Faced

Despite the promising future of transcatheter tricuspid valve technology, numerous challenges remain in its development.

First, in terms of device approval, the approval process for medical devices is stringent and complex, requiring extensive clinical trials and data verification to ensure their safety and efficacy. This process is not only time-consuming but also costly, and for Laplace Interventional, it necessitates a significant investment of human, material, and financial resources to meet regulatory requirements and obtain device approval.

Secondly, market competition is also an important challenge. With the gradual rise of the transcatheter tricuspid valve technology market, more and more companies and research institutions have begun to focus on and invest in the research and development of this field. Globally, several companies have already launched similar technologies and products, making market competition increasingly fierce.

Laplace Interventional needs to stand out among many competitors, not only by continuously improving its technical level but also by being competitive in terms of price, service, and other aspects.

▲Overview of Current Transcatheter Tricuspid Valve Intervention Products, Image Source: TCT Official Website

In addition, the technology itself needs further improvement. Although transcatheter tricuspid valve technology has achieved certain results, there are still some issues in practical applications, such as the long-term stability of the device and its adaptability to different patients' anatomical structures. These issues require further research and improvement to enhance the reliability and therapeutic effects of the technology.

# About Laplace Interventional

Laplace InterventionaLaplace Interventional, Inc. was founded in 2020 and is headquartered in Minnesota. The company was founded by Ramji Iyer and focuses on developing minimally invasive surgical technologies for the treatment of tricuspid regurgitation. Its representative product isLaplace TTVR System for Transcatheter Tricuspid Valve Replacement, avoiding traditional open-chest surgery. Currently, the system is still in the experimental stage and has not yet received approval from the FDA or other regulatory agencies.

Laplace Interventional has made significant progress in financing, recently completing a $22 million Series C funding round, following a $12.9 million Series B round. These funds will be used to complete the Early Feasibility Study (EFS) and prepare for pivotal clinical trials.